<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome rarely occurs in North America and Central Europe (incidence: 1 : 500,000), whereas it is more frequently seen in Japan and Mediterranean countries (incidence: 1 : 10,000) </plain></SENT>
<SENT sid="1" pm="."><plain>The diagnosis is based on the detection of symptoms and clinical signs </plain></SENT>
<SENT sid="2" pm="."><plain>Orogenital <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e>, anterior and posterior <z:e sem="disease" ids="C0042164" disease_type="Disease or Syndrome" abbrv="">uveitides</z:e> that frequently cause <z:hpo ids='HP_0000572'>loss of vision</z:hpo> are considered to be primary symptoms </plain></SENT>
<SENT sid="3" pm="."><plain>Dermatologic manifestations, i.e., <z:hpo ids='HP_0010783'>erythema</z:hpo> nodosum, vascular lesions (angio-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome), <z:mp ids='MP_0003300'>gastrointestinal ulcers</z:mp> and neurologic involvement, can be observed </plain></SENT>
<SENT sid="4" pm="."><plain>HLA B5 is found in some of the patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome </plain></SENT>
<SENT sid="5" pm="."><plain>Administration of <z:chebi fb="5" ids="28830">chlorambucil</z:chebi>, a cytotoxic compound, is an effective form of treatment of symptoms and complications of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome </plain></SENT>
<SENT sid="6" pm="."><plain>CASE REPORTS: The present article describes the course of a female and a male patient who were 39 and 23 years old when <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome was diagnosed for the first time </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> was started in the early 1990s and continued for a period of 9 1/2 and 3(3/4) years, respectively, with the symptoms remitting during and after this therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Approximately 10 years after the start of treatment with <z:chebi fb="5" ids="28830">chlorambucil</z:chebi>, the patients' symptoms changed </plain></SENT>
<SENT sid="9" pm="."><plain>The female patient who was first diagnosed having <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome at the age of 39 years developed <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> with joint destruction </plain></SENT>
<SENT sid="10" pm="."><plain>Her symptoms could be controlled in the long term by oral administration of <z:chebi fb="0" ids="8382">prednisone</z:chebi>, at doses below the Cushing threshold combined with <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>The male patient who was first diagnosed having <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome at the age of 23 years developed systemic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> remitting during low-dose treatment with <z:chebi fb="0" ids="8382">prednisone</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Immunosuppressive therapy with <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> administered over several years often induces remission of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome </plain></SENT>
<SENT sid="13" pm="."><plain>However, both case reports indicate that symptoms can change from <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome to systemic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> or <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> </plain></SENT>
</text></document>